High-Tech Gründerfonds, Bayern Kapital and BioM AG to invest in Intana Bioscience GmbH
July 6, 2009
Biochemical profiling services for companies in life science industry
Based on its proprietary fluorescence cross correlation spectroscopy (FCCS) Intana offers highly-specific biochemical profiling services for companies in the pharmaceutical, chemical and life science industries. FCCS is an interaction analysis based on a single molecule sensitive spectroscopic approach. The technology is extremely well suited to characterize molecular interactions between active ingredients, targets and off targets in cellular lysates. So far, the technology has been successfully employed for customers from the pharmaceutical industry in their drug discovery and development efforts. FCCS can be employed as an efficient tool to determine dissociation- and rate constants. High-Tech Gruenderfonds (HTGF), Bayern Kapital (SFB) and BioM AG jointly invested a total of 650,000 € in the start-up company.
“Customers benefit from short assay development times, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.” says Dr. Stefan Hannus, founder and managing director of Intana Bioscience GmbH. “Since we can work in cellular lysates our technology circumvents the need of protein purification. In addition, we do not need an activity assay, therefore enabling us to work with targets that cannot be efficiently addressed with current drug discovery technologies.”
“The funding will enable us to expand the application of our technology into additional fields, with the aim to establish and develop a stable business with a unique set of services for biotech- and pharmaceutical companies.” says Dr. Frank Becker, founder and managing director of Intana Bioscience GmbH. “The positive feedback from our customers convinced us, that the high quality data we generated indeed addresses the current needs of target based drug discovery.”
Dr. Michael Nettersheim, Investment Manager of the High-Tech Gruenderfonds Management GmbH comments: “It’s anything but new that drug developers demand for technologies which characterize novel compounds much quicker and more precisely. Intana’s FCCS-technology not only shortens development times but also makes any new target easily accessible under almost physiological conditions. Our investment accelerates the development of FCCS into additional and advanced applications.”
Andreas Huber, Investment Manager of Bayern Kapital GmbH, adds: “Intana`s innovative technology helps biotechnology and pharmaceutical companies to determine interaction between novel compounds and targets independent of the nature of the molecules and their function. Since protein purification is not required anymore assay development times are shortened which also means to save costs during the expensive drug development process.”
About High-Tech Gründerfonds:
The High-Tech Gründerfonds invests venture capital in young, up-and-coming technology companies, which implement promising research results in the industry. The start-up companies are planned to lead their R&D projects to the production of a prototype or a “proof of concepts” or market launch by means of the seed financing of up to 500k EUR. The High-Tech Gründerfonds has a fund volume of around 272m EUR. Investors of the public-private partnership are the Federal Ministry for Economics and Technology, the KfW bank group as well as the six industrial groups BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss.
High-Tech Gründerfonds Management GmbH
Dr. Michael Nettersheim
Ludwig-Erhard-Allee 253175 Bonn
Phone: +49 228 / 965685-00
Fax: +49 228 / 965685-50
About Seedfonds Bayern (SFB) from Bayern Kapital:
Seedfonds Bayern exists since 2003 and has a volume of 22 Mio. Euro to invest venture capital in young and innovative Bavarian technology-companies with high prospects that are transferring promising research results to business enterprises.The fund is managed by Bayern Kapital GmbH. Bayern Kapital GmbH is a Bavarian venture capital company and was founded as part of the “Bavarian Future Initiative” as a wholly-owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank) at the end of 1995. Bayern Kapital and its funds have invested about 142 Mio. Euro in more than 180 companies and currently manages funds to the value of 190 Mio. Euro.
For more information please contact www.bayernkapital.de